Innovent Biologics Inc/ADR
IVBXFDrugs in Pipeline
57
Phase 3 Programs
24
Upcoming Catalysts
16
Next Catalyst
This month
Market Overview
Stock performance and key metrics
16 upcoming, 1 past
Bortezomib for Injection
Relapsed or Refractory Multiple Myeloma
Sintilimab
Esophageal Squamous Cell Carcinoma
IBI362
Type 2 Diabetes
IBI306 450mg SC Q4W
Hypercholesterolemia
IBI306
Homozygous Familial Hypercholesterolemia
IBI311
Thyroid Eye Disease
tegafur, Gimeracil and Oteracil Potassium Capsules
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
IBI303
AS
IBI310
Advanced Cervical Cancer
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Aflibercept Ophthalmic
Neovascular Age-related Macular Degeneration
paclitaxel/Gemcitabine/Liposomal doxorubicin
Ovarian
Platinum
Lung Neoplasms
Investigator's choice of therapy
Colorectal Cancer
IBI305
Non-Squamous Non-Small Cell Lung Cancer
IBI343
Pancreatic Cancer
IBI354
Locally Advanced Unresectable or Metastatic Solid Tumors
Febuxostat
Gout
IBI308
Esophageal Squamous Cell Carcinoma
IBI305 in Combination with Paclitaxel/Carboplatin
NSCLC
IBI301 plus CHOP
Diffuse, Large B-Cell, Lymphoma
IBI310&Sintilimab
MSI-H
IBI112
Psoriasis
Picankibart
Plaque Psoriasis
IBI343,Gemcitabine, Albumin-bound Paclitaxel
CLDN18.2 Positive
IBI128
Gout
Pemigatinib
Cholangiocarcinoma
IBI3014
Unresectable Locally Advanced or Metastatic Solid Tumors
IBI133
Locally Advanced Unresectable or Metastatic Solid Tumors
IBI3002
Atopic Dermatitis
IBI302
Diabetic Macular Oedema
dose 1 IBI302
Neovascular Age-related Macular Degeneration
Period 2 IBI112 dose 3
Ulcerative Colitis (UC)
GFH925
KRAS G12C
IBI356
Atopic Dermatitis
HAIC
Hepatocellular Carcinoma
Cardunolizumab
Vulvar and Vaginal Cancer
Tafolecimab
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
IBI351 combined with cetuximab β
Lung Cancer (Non-Small Cell)
sintilimab combined with anlotinib
NSCLC
IBI3016
Hypertension
Keytruda
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
fulzerasib
Resectable NSCLC
Chidamide in combination with Ivonescimab
Non-Small Cell Lung Cancer
IBI311 (20 mg)
Thyroid Eye Disease
Low dose IBI302
Neovascular Age-related Macular Degeneration
IBI3003
Multiple Myeloma
IBI112 dose 2
Psoriasis
PD1
Relapsed/Refractory Classical Hodgkin's Lymphoma
IBI376
Indolent Non-hodgkin Lymphoma
IBI363
Melanoma
IBI334
Advanced Solid Tumors
IBI130
Solid Tumor
IBI129
Solid Tumor
IBI343,sintilimab,oxaliplatin,S-1
CLDN18.2 Positive
IBI302 8mg dose
Neovascular Age-related Macular Degeneration
regular treatment
Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bortezomib for Injection | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Sintilimab | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
IBI362 | Phase 3 | Type 2 Diabetes | - | - |
IBI306 450mg SC Q4W | Phase 3 | Hypercholesterolemia | - | - |
IBI306 | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
IBI311 | Phase 3 | Thyroid Eye Disease | - | - |
tegafur, Gimeracil and Oteracil Potassium Capsules | Phase 3 | Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | - | - |
IBI303 | Phase 3 | AS | - | - |
IBI310 | Phase 3 | Advanced Cervical Cancer | - | - |
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） | Phase 3 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | - | - |
Aflibercept Ophthalmic | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
paclitaxel/Gemcitabine/Liposomal doxorubicin | Phase 3 | Ovarian | - | - |
Platinum | Phase 3 | Lung Neoplasms | - | - |
Investigator's choice of therapy | Phase 3 | Colorectal Cancer | - | - |
IBI305 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
IBI343 | Phase 3 | Pancreatic Cancer | - | - |
IBI354 | Phase 3 | Locally Advanced Unresectable or Metastatic Solid Tumors | - | - |
Febuxostat | Phase 3 | Gout | - | - |
IBI308 | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
IBI305 in Combination with Paclitaxel/Carboplatin | Phase 3 | NSCLC | - | - |
IBI301 plus CHOP | Phase 3 | Diffuse, Large B-Cell, Lymphoma | - | - |
IBI310&Sintilimab | Phase 3 | MSI-H | - | - |
IBI112 | Phase 3 | Psoriasis | - | - |
Picankibart | Phase 3 | Plaque Psoriasis | - | - |
IBI343,Gemcitabine, Albumin-bound Paclitaxel | Phase 2 | CLDN18.2 Positive | - | - |
IBI128 | Phase 2 | Gout | - | - |
Pemigatinib | Phase 2 | Cholangiocarcinoma | - | - |
IBI3014 | Phase 2 | Unresectable Locally Advanced or Metastatic Solid Tumors | - | - |
IBI133 | Phase 2 | Locally Advanced Unresectable or Metastatic Solid Tumors | - | - |
IBI3002 | Phase 2 | Atopic Dermatitis | - | - |
IBI302 | Phase 2 | Diabetic Macular Oedema | - | - |
dose 1 IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
Period 2 IBI112 dose 3 | Phase 2 | Ulcerative Colitis (UC) | - | - |
GFH925 | Phase 2 | KRAS G12C | - | - |
IBI356 | Phase 2 | Atopic Dermatitis | - | - |
HAIC | Phase 2 | Hepatocellular Carcinoma | - | - |
Cardunolizumab | Phase 2 | Vulvar and Vaginal Cancer | - | - |
Tafolecimab | Phase 2 | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | - | - |
IBI351 combined with cetuximab β | Phase 2 | Lung Cancer (Non-Small Cell) | - | - |
sintilimab combined with anlotinib | Phase 2 | NSCLC | - | - |
IBI3016 | Phase 2 | Hypertension | - | - |
Keytruda | Phase 2 | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | - | - |
fulzerasib | Phase 2 | Resectable NSCLC | - | - |
Chidamide in combination with Ivonescimab | Phase 2 | Non-Small Cell Lung Cancer | - | - |
IBI311 (20 mg) | Phase 2 | Thyroid Eye Disease | - | - |
Low dose IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
IBI3003 | Phase 2 | Multiple Myeloma | - | - |
IBI112 dose 2 | Phase 2 | Psoriasis | - | - |
PD1 | Phase 2 | Relapsed/Refractory Classical Hodgkin's Lymphoma | - | - |
IBI376 | Phase 2 | Indolent Non-hodgkin Lymphoma | - | - |
IBI363 | Phase 2 | Melanoma | - | - |
IBI334 | Phase 2 | Advanced Solid Tumors | - | - |
IBI130 | Phase 2 | Solid Tumor | - | - |
IBI129 | Phase 2 | Solid Tumor | - | - |
IBI343,sintilimab,oxaliplatin,S-1 | Phase 2 | CLDN18.2 Positive | - | - |
IBI302 8mg dose | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
regular treatment | Phase 2 | Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Innovent Biologics Inc/ADR's drug pipeline?→
CatalystAlert tracks 57 drug candidates in Innovent Biologics Inc/ADR's (IVBXF) pipeline across Phase 3, Phase 2. Its lead program is Bortezomib for Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Innovent Biologics Inc/ADR's next FDA catalyst?→
Innovent Biologics Inc/ADR's (IVBXF) next tracked catalyst is a Phase 2 expected September 24, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IVBXF biotech catalysts?→
Add IVBXF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Innovent Biologics Inc/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.